Kevin Hrusovsky, President, CEO and Chairman of Quanterix, recently spoke to Edwin Warfield of CityBizList Boston to discuss the science behind Quanterix, its NIH work and the company’s prospects. You will quickly understand that he and Quanterix are on a mission to transform medicine.
In The News
CityBizList | Edwin Warfield | October 29, 2020
WCVB News 5 Boston | October 09, 2020
Ted Wayman reports on the recent $20 million contract awarded to Quanterix by the National Institutes of Health to see if their blood test for COVID-19 is more accurate than the current nasal swab test.
Outsourcing Pharma | July 20, 2020
Kevin Hrusovsky, Quanterix CEO, Chairman, and President and Founder of Powering Precision Health talks about how PPH, an innovation-minded nonprofit organization aims to foster collaboration among scientists and tech minds, to fuel discovery and accelerate therapies.
Clinical Lab Products | June 08, 2020
Quanterix, Billerica, Mass, is expanding its menu of ready-to-use Simoa kits to include tau phosphorylated at threonine 181 (p-tau 181), a highly specific biomarker for the study of Alzheimer’s disease pathology in cerebrospinal fluid, plasma, and serum.
Ultra-sensitive Simoa technology powers a new COVID-19 antibody test that can detect antibodies at 1000x lower concentrations
WCVB News 5 | May 12, 2020
Ultra-sensitive Simoa technology powers a new COVID-19 antibody test that can detect antibodies at 1000x lower concentrations. Quanterix CEO Kevin Hrusovsky and Dr.